Acceleron blood disease drug hits goal in pivotal clinical trial

Acceleron blood disease drug hits goal in pivotal clinical trial

Source: 
Stat
snippet: 

Acceleron Pharma said Thursday that its experimental drug luspatercept significantly reduced the need for blood transfusions in patients with the blood disease myelodysplastic syndrome, meeting the primary goal of a Phase 3 clinical trial.